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Objective: It has been argued that health status and quality of life (QOL) should be taken into account in the treatment
policy of patients with peripheral arterial disease (PAD). In cardiac patients, it has been shown that poor perceived health
status is an independent predictor of mortality and hospitalization. We therefore examined (1) the role of health status,
QOL, and clinical indices of disease severity as determinants of invasive treatment in patients with PAD and (2) the effect
of invasive treatment on health status and QOL.
Methods:At their first visit, patients completed the RAND36-itemHealth Survey andWorldHealthOrganizationQuality
of Life assessment instrument questionnaires to assess health status and QOL, respectively. During the 1-year follow-up
period, data concerning hospitalization were derived from the patients’ medical files. Furthermore, patients completed
the RAND 36 and the World Health Organization Quality of Life assessment instrument again at 1-year follow-up. The
setting was a vascular outpatient clinic of a teaching hospital in Tilburg, The Netherlands; participants were 200
consecutive patients newly diagnosed with intermittent claudication, a common expression of PAD. Diagnosis was based
on history, physical examination, treadmill walking distance, and ankle-brachial pressure indices.Main outcomemeasures
were (1) invasive treatment of PAD that took place during the 1-year follow-up, derived from the patients’ medical files,
and (2) health status and QOL after 1 year of follow-up.
Results: After 1 year of follow-up, 107 patients (53.5%) were event free, whereas 77 patients (38.5%) had been
hospitalized for invasive treatment of PAD. Sixteen patients (8%) were hospitalized for other cardiovascular reasons. In
a multivariate logistic regression model, age (odds ratio [OR], 0.95; 95% confidence interval [CI], 0.91-0.99; P .024),
pain-free walking distance (OR, 2.74; 95% CI, 1.05-7.17; P  .04), and physical functioning (OR, 4.46; 95% CI,
1.79-11.12; P  .001) were independent predictors of invasive treatment of intermittent claudication. After 1 year of
follow-up, patients who were treated invasively experienced a significant improvement in their physical functioning (P
.004), role limitations due to emotional problems (P  .018), and bodily pain (P  .026).
Conclusions: Patients with poor self-reported physical functioning, limited walking distance, and a younger age were likely
to be treated invasively. The physician’s clinical judgment about when to intervene adequately reflects the patient’s own
opinion about his or her health status. Invasive treatment led to a significant improvement in patients’ health status.
These findings indicate the effectiveness of the strategy to include patients’ perceived physical functioning into the process
of clinical decision-making. (J Vasc Surg 2005;41:436-42.)Because of the chronic, progressive nature of athero-
sclerosis, self-reported health status and quality of life
(QOL) have become increasingly important outcome mea-
sures for evaluating the effect of therapeutic interventions
from patients’ perspective.1-3 Coronary artery disease, ce-
rebrovascular disease, and peripheral arterial disease (PAD)
are common expressions of atherosclerosis. Recently, it has
been argued that health status and QOL should also be
taken into account in the treatment policy of PAD pa-
tients.4-6 In cardiac patients, it has already been shown that
poor perceived health status is an independent predictor of
mortality and hospitalization.7-11 In PAD patients, preop-
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436erative health perceptions are related to surgical out-
come.12 These preliminary findings indicate the need to
determine the predictive value of health status and QOL
measures regarding invasive treatment of PAD.
The aim of this prospective study was twofold. First, we
wanted to know whether the physician’s clinical judgment in
deciding when to intervene corresponds with the patient’s
health status and QOL. Therefore, we examined whether
subjective reports of impaired health status and QOL are
significant determinants of invasive treatment of PAD, in
addition to clinical indices of PAD severity. Second, we
wanted to know whether patients who underwent invasive
treatment were better off in terms of health status and QOL.
Therefore, we examined the effect of invasive treatment on
patients’ health status and QOL after 1 year of follow-up.
METHODS
Patients Between January 1999 and June 2000, base-
line health status and QOL data were assessed in 200
consecutive patients presenting with intermittent claudica-
tion (IC; pain during ambulation), a common symptom of
axima
ion.
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surgery at the St Elisabeth Hospital in Tilburg, The Neth-
erlands. Patients were referred by their general practitioners
for evaluation and diagnosis. All patients were newly diag-
nosed with IC on the basis of history, physical examination,
treadmill walking, and ankle-brachial pressure indices
(ABPI). IC was classified as mild, moderate, or severe
according to the Society for Vascular Surgery/North
American Chapter of the International Society for Cardio-
vascular Surgery.13 The characteristics of the 200 partici-
pating patients are shown in Table I. The mean age of the
total study population was 62.8 years (range, 42-83 years).
Detailed descriptions of the study population have been
Table I. Baseline characteristics of 200 patients with inter
Variable n
Male/female sex 135/65
Age (y)
Unilateral/bilateral disease 130/70
ABPI
PFWD (m)
MWD (m)
Mild claudication† 37
Moderate claudication‡ 81
Severe claudication§ 82
Diabetes mellitus 32
Tobacco use 132
Hypertension 94
Hyperlipidemia 106
Cardiac status 64
Carotid status 28
Renal status 8
Pulmonary status 20
ABPI, Ankle-brachial pressure index; PFWD, pain-free treadmill walking di
†Mild claudication: completes modified treadmill exercise;* ankle pressure
‡Moderate claudication: between mild and severe.
§Severe claudication: cannot complete modified treadmill exercise, and ankle
of 1000 m.
*The Society for Vascular Surgery/North American Chapter of the Interna
factors is as follows (all risk factors were recoded into absent [0] or present
Diabetes: 0, none; 1, adult onset, controlled by diet or oral agents; 2, adult
Smoking: 0, none or none for last 10 years; 1, none current, but smoked in
per day; 3, current, more than one pack per day.
Hypertension: 0, none, diastolic pressure usually lower than 90 mm Hg; 1,
two drugs or uncontrolled.
Hyperlipidemia: 0, cholesterol (low-density lipoprotein and total) and trig
requiring strict dietary control; 3, requiring dietary and drug control.
Cardiac status: 0, asymptomatic, normal electrocardiogram; 1, asymptom
infarction by electrocardiogram, or fixed defect on dipyridamole thallium
perfusion defect on dipyridamole thallium scan, significant silent ischemia (
ectopy or asymptomatic arrhythmia, history of congestive heart failure that
controlled ectopy or arrhythmia, poorly compensated or recurrent conges
months.
Carotid disease: 0, no symptoms and no evidence of disease; 1, asymptom
noninvasive test or arteriogram; 2, transient or temporary stroke; 3, comple
Renal status (refers to stable levels, not transient decreases or increase in resp
disease, normal serum creatinine; 1, moderately increased creatinine level,
mg/dL, or on dialysis or with kidney transplant.
Pulmonary status: 0, asymptomatic, normal chest x-ray film, pulmonary fun
mild chronic parenchymal x-ray changes, pulmonary function test 65% to
expiratory volume in 1 second less than 1.2 L or less than 35% of predicted, m
Hg, supplemental oxygen use medically necessary, or pulmonary hypertenspublished elsewhere.6 In brief, IC was suspected in 215patients and could be confirmed in 207 patients. Of these
patients, seven refused participation or were not able to
participate. After 1 year, the patients were asked to com-
plete health status and QOL questionnaires again. Of the
entire study group, 156 patients (78%) filled in the ques-
tionnaires after 1 year. Of the invasively treated patients,
22% refused to complete the questionnaires at follow-up, vs
23% of the event-free patients. No differences between the
responders and the nonresponders were found in age,
ABPI, pain-free treadmill walking distance (PFWD), max-
imum treadmill walking distance (MWD), cardiovascular
risk factors, or baseline health status and QOL data. The
study was approved by the local ethics committee, and all
nt claudication
% Mean (range) Median
/32.5
62.8 (42-83)
/35
0.62 (0.24-0.95)
100.2 (0-1000) 80
398.4 (40-1000) 245
8.5
0.5
1
6
6
7
3
2
4
4
0
; MWD, maximum treadmill walking distance.
xercise is 50 mmHg but at least 20 mm Hg lower than resting value.
re after exercise is50 mm Hg.* 3.5 km/h on a 5% incline with a maximum
Society for Cardiovascular Surgery grading system13 for cardiovascular risk
or 3], except for smoking [absent, 0 or 1; present, 2 or 3]).
, insulin controlled; 3, juvenile onset.
0 years; 2, current (includes abstinence less than 1 year), less than one pack
olled with single drug; 2, controlled with two drugs; 3, requires more than
des within normal limits for age; 1, mild increase, controllable by diet; 2,
emote myocardial infarction by history (6 months), occult myocardial
ilar scan; 2, any one of stable angina, no angina but significant reversible
f the time) on Holter monitoring, ejection fraction 25% to 45%, controlled
well compensated; 3, any one of unstable angina, symptomatic or poorly
art failure, ejection fracture less than 25%, myocardial infarction within 6
ut with evidence of disease determined by duplex scan or other accepted
roke with permanent neurologic deficit or acute stroke.
o intravenous medication, hydration, or contrast media): 0, no known renal
as 2.4 mg/dL; 2, creatinine level, 2.5 to 5.9 mg/dL; 3, creatinine 6.0
test within 20% of predicted; 1, asymptomatic or mild dyspnea on exertion,
f predicted; 2, between 1 and 3; 3, vital capacity less than 1.85 L, forced
l voluntary ventilation less than 50% of predicted, PCO2 greater than 45 mmmitte
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Disease severity. In all patients, the PFWD, MWD,
ABPI were measured as indices of severity of PAD. The
ABPI is defined as the ratio of the ankle systolic blood
pressure to the brachial artery systolic blood pressure and
has a normal resting value of approximately 1.0.14 A value
of 0.9 has been shown to be highly sensitive to detect
PAD.5
Cardiovascular risk factors. Smoking, hyperlipid-
emia, diabetes mellitus, hypertension, and cardiac, carotid,
renal, and pulmonary status were registered at baseline
according to the Society for Vascular Surgery/North
American Chapter of the International Society for Cardio-
vascular Surgery criteria.13 In addition, the presence of
back, knee, and hip symptoms unrelated to PAD was also
recorded.
Health status. The RAND 36-Item Health Survey
(RAND 36)15,16 is a 36-item generic health status measure
that assesses eight concepts: (1) physical functioning, (2)
social functioning, (3) role limitations due to physical prob-
lems, (4) role limitations due to emotional problems, (5)
mental health, (6) vitality, (7) bodily pain, and (8) general
health perception. The RAND 36 and the Medical Out-
comes Study Short Form-3617 are similar health status
measures; however, concerning the dimensions bodily pain
and general health perception, the scoring is somewhat
different.15 The RAND 36 has good reliability and
validity.18
Quality of life. The World Health Organization
QOL assessment instrument-100 (WHOQOL-100) is a
generic QOL measure that consists of 100 questions assess-
ing QOL with 24 facets in 6 domains.19,20 In this study, an
abbreviated version of the WHOQOL-100 was used that
had previously been reduced for the specific patient popu-
lation.6 This version included three QOL-domains: (1)
physical health, (2) level of independence, and (3) social
relationships.6 The WHOQOL-100 has good reliability
and validity20 and is sensitive to treatment-related
change.21
Invasive treatment of PAD
Invasive treatment of PAD was used as an end point in
this study. Although the general treatment policy for pa-
tients with IC is merely conservative—ie, 3 months of
unsupervised exercise training, advice to quit smoking, and
antiplatelet medication—this does not always lead to sig-
nificant improvements in (pain-free) walking distance. In-
vasive therapy is then considered by the vascular surgeon.
However, in case of severe impairment, or when conserva-
tive treatment is not expected to improve the patient’s
functioning, invasive treatment is considered sooner. Dur-
ing the 1-year follow up period, hospital admission was
prospectively examined by using the patient records from
the participating hospital. All patients who underwent in-
vasive treatment were hospitalized. Invasive procedures
were performed in the St Elisabeth Hospital. If a patient
were admitted to another hospital or abroad, this informa-tion would be obtained from the patient records of the St
Elisabeth Hospital. Patients who were not hospitalized at
all during the 1-year follow-up period were considered to
be event free. Patients were excluded if they were hospital-
ized for cardiovascular reasons other than invasive treat-
ment of PAD (Table II). Furthermore, it was determined
whether hospitalization was early or late. Patients were
classified as being hospitalized early when invasive treat-
ment occurred within 3 months after inclusion. They were
classified as being hospitalized late if invasive treatment
took place later than 3 months after inclusion. All 200
patients were followed up throughout the study period
with regard to hospital admission.
Statistical analyses
Univariate logistic regression analyses were used to
examine the predictive value of clinical variables, health
status, and QOL with regard to invasive treatment for IC.
Therefore, ABPI, PFWD, and MWD were dichotomized
into low scores (first quartile) vs average or high scores.
This led to a cutoff score of 0.51 for ABPI, which is in
accordance with previous studies.14,22 Cutoff scores for
PFWD and MWD were 40 and 130 m, respectively. In
addition, the scores on the subscales of the RAND 36 and
WHOQOL questionnaire were divided into low scores
(first quartile) vs average or high scores. For example,
scores on the RAND physical functioning scale were con-
sidered low if 35 (first quartile). Healthy elderly patients
(55-64 years) have a mean score of 72.7 on this scale; this
indicates far better health status.16 The cardiovascular risk
Table II. Reasons for invasive treatment of IC (n  77)
and other cardiovascular-related hospitalizations (n  16)
in patients with intermittent claudication during 1 year of
follow-up
Variable n
Invasive treatment of IC
Percutaneous transluminal angioplasty 56
Bypass 13
Percutaneous transluminal angioplasty and bypass 4
Endarterectomy 2
Amputation 2
Total 77
Other
Myocardial infarction 4
Angina pectoris 1
Cardioversion 3
Coronary artery bypass grafting 1
Heart failure 2
Atrial fibrillation 1
Angina pectoris and myocardial infarction 1
Angina pectoris and endarterectomy (aorta) 1
Transient ischemic attack 1
Percutaneous transluminal angioplasty (renal
artery)
1
Total 16
Total hospitalizations 93
IC, Intermittent claudication.factors were dichotomized to absent or present. Significant
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ous analyses, age, sex, ABPI, and PFWD were included in
multivariate logistic regression analyses (forward condi-
tional method), with invasive treatment as the end point.
The final multivariate logistic regression analysis (enter
method) included age, sex, ABPI, PFWD, and the signifi-
cant health status and QOL predictors. This model was
tested separately for patients who were treated early and
late. The event-free patients were used as the reference
group. Analyses of variance for repeated measures were
used to compare groups (invasively treated vs event free)
over time on the eight subscales of the RAND 36 and the
three QOL domains. Student t tests were performed to
compare invasively treated patients with event-free patients
on health status and QOL at 1 year of follow-up. All
statistical analyses were performed with SPSS version 11.5
(SPSS Inc, Chicago, Ill).
RESULTS
After 1 year of follow-up, 77 patients (38.5%) had been
hospitalized for invasive treatment of PAD (Table II). Of
these patients, 11 had progressed to rest pain or pain at
night, whereas 3 patients were treated for tissue loss. One
hundred seven patients (53.5%) were event free. Further-
more, 16 patients (8%) were hospitalized for other cardio-
vascular reasons, such as coronary artery bypass grafting
(Table II).
Disease severity and invasive treatment. Using uni-
variate regression analyses, limited PFWD was found to be
a predictor of invasive treatment, with an odds ratio (OR)
of 3.51 (95% confidence interval [CI], 1.62-7.60; P 
.001). Invasively treated patients had the shortest PFWD
(mean, 86.8 m), whereas event-free patients had a mean
PFWD of 113.7 m. Low ABPI and short MWD were not
related to invasive treatment during follow-up. In addition,
smoking (OR, 2.04; 95% CI, 1.06-3.92; P .034) was the
only cardiovascular risk factor that predicted invasive treat-
ment in patients with IC. Patients who were treated inva-
sively were more likely to be smokers as compared with
event-free patients. Back, knee, and hip symptoms (unre-
Table III. Independent predictors of invasive treatment
of IC using multivariate logistic regression analysis
Multivariate predictors of
invasive treatment for IC OR 95% CI P value
Poor physical functioning 4.46 1.79-11.12 .001
PFWD 40 m 2.74 1.05-7.17 .040
ABPI 0.51 0.96 0.39-2.33 .924
Smoking 1.19 0.47-2.99 .716
Covariates
Age* 0.95 0.91-0.99 .024
Sex 0.68 0.30-1.56 .366
IC, Intermittent claudication; OR, odds ratio; CI, confidence interval;
PFWD, pain-free treadmill walking distance; ABPI, ankle-brachial pressure
index.
*Age was entered as a continuous variable.lated to PAD) were unrelated to invasive treatment.Health status, QOL, and invasive treatment. Poor
physical functioning (OR, 4.32; 95% CI, 2.01-9.29; P 
.001), role limitations due to emotional problems (OR,
2.09; 95% CI, 1.02-4.30; P  .045), and poor mental
health (OR, 2.02; 95% CI, 1.01-4.02; P  .046) were
univariate health status predictors of invasive treatment.
Concerning QOL, poor physical health (OR, 2.09; 95%
CI, 1.06-4.13; P  .034) was a predictor of invasive
treatment. Multivariate logistic regression analysis, includ-
ing the significant health status and QOL predictors, indi-
cated that RAND 36 physical functioning remained as the
only independent predictor of invasive treatment of IC
(OR, 4.48; 95% CI, 1.98-0.12; P  .001).
Independent predictors of invasive treatment. The
final multivariate logistic regression analysis, with invasive
treatment as the end point, included age, sex, PFWD,
ABPI, smoking, and the RAND 36 domain physical func-
tioning. Because the previous univariate analyses showed
that none of the other cardiovascular risk factors or the
presence of back, knee, and hip symptoms (unrelated to
PAD) could predict invasive treatment in patients with IC,
it was decided to exclude these variables from the final
model. Results showed that younger age, limited PFWD,
and poor physical functioning were independent predictors
of invasive treatment of IC (Table III).
The previous analysis yielded both an index of disease
severity and a measure of health status as determinants of
invasive treatment. Therefore, patients were classified ac-
cording to their scores on PFWD and the RAND 36 scale
physical functioning (high vs low). This led to four patient
subgroups (Fig 1). The percentages of invasive treatment
were highest in patients with poor physical functioning,
Fig 1. Invasive treatment as a function of pain-free treadmill
walking distance (PFWD) and RAND 36-item Health Survey
subscale physical functioning at baseline.both with and without limited walking distance. In patients
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talization differed significantly between patients with good
and poor physical functioning.
Early vs late invasive treatment. Within the group of
invasively treated patients, 45 patients (58.4%) were hospi-
talized early. Thirty-two patients (41.6%) were hospitalized
after the 3-month period after inclusion. To determine
whether poor health status predicted both early and late
invasive treatment, the final regression model was tested
separately for patients who were hospitalized early and
patients who were hospitalized late. Younger age (OR,
0.95; 95% CI, 0.90-0.99; P  .029) and poor physical
functioning (OR, 4.6; 95% CI, 1.64-12.97; P .004) were
both independent predictors of invasive treatment within 3
months after inclusion, whereas short PFWD (OR, 4.8;
95% CI, 1.32-17.03; P .017) and poor physical function-
ing (OR, 4.7; 95% CI, 1.30-16.98; P .018) predicted late
invasive treatment.
Effect of invasive treatment on health status and
QOL. Regarding health status, there was a general signif-
icant improvement for all patients in physical functioning
(P .0001), role limitations due to physical problems (P
.013), and bodily pain (P  .0001, indicating less pain)
between 0 and 12 months. The significant interaction effect
for time  invasive treatment indicated that patients who
were treated invasively experienced a significantly greater
improvement in their physical functioning (P .004), role
limitations due to emotional problems (P  .018), and
bodily pain (P .026), as compared with patients who had
conservative treatment (Fig 2).
Concerning QOL, a general improvement was found
for all patients in physical health (P  .010) and level of
independence (P  .016), whereas social relationships had
deteriorated (P  .001) between 0 and 12 months. No
significant effect was found for invasive treatment regarding
the domains of the WHOQOL. At 12 months of follow-
up, no significant differences remained in health status or
QOL between invasively treated patients and event-free
patients (all P values were .22).
DISCUSSION
In this study, health status and QOL were examined in
relation to invasive treatment in patients with PAD. The
results demonstrated that IC patients with poor physical
functioning (RAND 36), a short PFWD, and a younger age
were likely to be treated invasively. It is important to note
that invasive treatment led to significant improvements in
patients’ health status at 1 year of follow-up. These findings
indicate the effectiveness of the strategy of including pa-
tients’ perceived physical functioning into the process of
clinical decision making.
Given the risk of possible complications and increasing
health-care costs, invasive treatment for disabling IC re-
mains controversial.23 IC is generally a benign condition24
that mostly requires conservative treatment and modifica-
tion of risk factors.25,26 However, previous studies have
shown that IC causes significant impairments in health
status and QOL.27,28 It has been suggested that invasivetreatment not only should be based on PFWD, but may
also be considered when symptoms interfere with a pa-
tient’s lifestyle or occupation,24 thus causing poor
QOL.5,29,30 Patients who underwent invasive treatment
were better off in terms of health status than patients who
were treated conservatively, indicating that including self-
reported health status in the decision to intervene was an
effective strategy.
A younger age and poor physical functioning, as re-
ported by the patients themselves, were independent pre-
dictors of invasive treatment within 3 months. Younger
claudicants often have more demanding lifestyles than
older patients; invasive treatment could therefore be more
suitable for these patients. Information regarding self-
reported physical functioning could be very useful for vas-
cular surgeons when deciding which patients need invasive
treatment.
After 3 months, impaired PFWD and poor physical
functioning were the main reasons for invasive treatment.
This may indicate that some patients were treated conser-
Fig 2. Health status at 0 and 12 months, stratified by invasive
treatment.vatively at first but that, because of their impaired PFWD
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perform invasive treatment after all. Although PFWD was a
strong predictor, none of the other clinical variables, such
as ABPI or MWD, could predict invasive treatment. Previ-
ous studies31,32 have shown that a low ABPI was associated
with cardiovascular mortality and morbidity in patients
with PAD. In this study, only a few patients were hospital-
ized because of cardiovascular reasons other than invasive
treatment of PAD; it was therefore not possible to deter-
mine the predictive value of ABPI regarding cardiovascular
morbidity as a secondary end point. This could be due to
the relatively short 1-year follow-up period, which is also
one of the limitations of this study. A longer follow-up
period would be better for obtaining more information on
morbidity and mortality. Furthermore, McDermott et al32
found that patients with an ABPI 0.3, indicating critical
limb ischemia, had significantly poorer survival than pa-
tients with a higher ABPI. In this study, only patients with
IC were included, which could make generalization of the
results to other forms of PAD difficult. Because patients
with chronic critical limb ischemia are often elderly and
frail, their long-term survival is worse than in patients with
IC.33
The findings of this study have implications for further
clinical research and practice. Recent guidelines2,5 empha-
size the importance of assessing outcomes from patients’
perspective. It is also argued that information regarding
QOL and health status should be included in treatment
policy. The findings from this study support this notion.
Patients who reported low physical functioning were more
likely to be treated invasively. It is therefore important to
integrate patient-reported health status and QOL data with
the clinical care of patients with PAD. Although it has
previously been stated that surgeons predict the QOL of IC
patients less accurately than patients do themselves,29 this
study showed that the physician’s decision about when to
intervene accurately reflects the patient’s own opinion
about his or her health status. Moreover, invasive treatment
had a positive effect on patients’ health status. For example,
patients’ physical functioning improved by more than 20
points after invasive treatment. By using objective patient-
reported health status data in the management of PAD and
subsequently detecting the patients who report low physi-
cal functioning, outcomes could be improved, and more
accurate treatment options could be provided for this pa-
tient group in the future.
This study showed that physical functioning was an
independent predictor of invasive treatment. The health
status subscale physical functioning assesses functional lim-
itations caused by disease. It is a measure of a patient’s
functioning. QOL assesses the patient’s own evaluation of
his or her physical functioning. In other words: is a patient
satisfied or dissatisfied with his or her level of physical
functioning? Only the health status subscale physical func-
tioning, and not the QOL subscale, predicted invasive
treatment in multivariate analyses. Therefore, we can con-
clude that the functional limitations caused by disease are
the main determinants of intervention. The reporting ofphysical symptoms and impairments (health status)—not
patients’ perception of the symptoms and impairments
(QOL)—determined invasive treatment.
In conclusion, these findings demonstrate that the
physician’s clinical judgment about when to intervene ad-
equately reflects the patient’s health status. Poor self-
reported physical functioning predicted invasive treatment
in patients with IC, even after controlling for clinical vari-
ables. The physician’s decision about when to intervene is
thus not based solely on clinical indicators such as PFWD or
a younger age, but it also reflects the patient’s own opinion
about his or her health status. This may be an effective
strategy, because invasive treatment led to significant im-
provements in patients’ health status at 1 year of follow-up.
Hence, this study provides evidence for the predictive value
of perceived physical functioning in addition to traditional
clinical indicators with regard to invasive treatment of IC.
Self-reported physical functioning should be assessed in
patients with PAD, in addition to traditional clinical mea-
sures.
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Managing Coding and Reimbursement Challenges in 
Vascular Surgery 2005 
March 11 
Wyndham San Diego at 
Emerald Plaza
San Diego, CA 
September 23 
Hyatt Regency Atlanta 
Atlanta, GA 
Take the mystery out of coding for vascular surgery—
make time to attend the Society for Vascular Surgery’s 
coding and reimbursement course. This one-day program, 
which was offered for the first time in 2004, is held in 
conjunction with Karen Zupko & Associates, Inc. and has 
been fully updated for 2005. You will leave the program 
with a new understanding of the 2005 CPT and ICD-9-CM 
and Medicare updates, principles of component coding, 
plus correct coding for key vascular surgery cases and 
vascular lab services—and more. 
For more information or to register, visit the SVS website, www.vascularweb.org and 
